Belpointe Asset Management LLC purchased a new stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON – Get Rating) during the fourth quarter, Holdings Channel.com reports. The fund purchased 409 shares of the biotechnology company’s stock, valued at approximately $68,000.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. UBS Group AG boosted its stake in shares of Axon Enterprise by 65.4% in the 4th quarter. UBS Group AG now owns 110,716 shares of the biotechnology company’s stock worth $18,371,000 after buying an additional 43,779 shares during the last quarter. Montanaro Asset Management Ltd raised its stake in shares of Axon Enterprise by 17.3% during the 4th quarter. Montanaro Asset Management Ltd now owns 31,150 shares of the biotechnology company’s stock worth $5,169,000 after purchasing an additional 4,600 shares during the period. Thrivent Financial for Lutherans boosted its holdings in shares of Axon Enterprise by 0.8% in the 4th quarter. Thrivent Financial for Lutherans now owns 18,008 shares of the biotechnology company’s stock worth $2,988,000 after buying an additional 137 shares during the last quarter. California Public Employees Retirement System grew its position in Axon Enterprise by 11.2% during the fourth quarter. California Public Employees Retirement System now owns 148,304 shares of the biotechnology company’s stock valued at $24,608,000 after buying an additional 14,982 shares during the period. Finally, Swiss National Bank increased its holdings in Axon Enterprise by 1.9% during the fourth quarter. Swiss National Bank now owns 163,100 shares of the biotechnology company’s stock worth $27,063,000 after buying an additional 3,100 shares during the last quarter. 75.62% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several brokerages have recently issued reports on AXON. Raymond James lowered shares of Axon Enterprise from a “strong-buy” rating to an “outperform” rating and set a $223.00 price target for the company. in a research note on Friday, February 17th. The Goldman Sachs Group assumed coverage on Axon Enterprise in a research report on Tuesday, March 7th. They set a “buy” rating and a $263.00 price target on the stock. JPMorgan Chase & Co. upgraded Axon Enterprise from a “neutral” rating to an “overweight” rating and set a $236.00 price objective on the stock in a research note on Thursday, May 11th. JMP Securities reiterated a “market outperform” rating and set a $235.00 target price on shares of Axon Enterprise in a research report on Friday, April 14th. Finally, Credit Suisse Group boosted their price target on shares of Axon Enterprise from $300.00 to $309.00 in a research report on Wednesday, May 10th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $232.64.
Insider Activity at Axon Enterprise
Axon Enterprise Stock Performance
Shares of AXON opened at $196.86 on Monday. Axon Enterprise, Inc. has a 12-month low of $83.01 and a 12-month high of $229.95. The company has a current ratio of 3.33, a quick ratio of 2.97 and a debt-to-equity ratio of 0.48. The company has a market cap of $14.55 billion, a PE ratio of 104.16 and a beta of 0.95. The stock has a 50-day moving average price of $216.57 and a 200-day moving average price of $196.61.
Axon Enterprise (NASDAQ:AXON – Get Rating) last released its quarterly earnings results on Tuesday, February 28th. The biotechnology company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.28. Axon Enterprise had a net margin of 10.76% and a return on equity of 10.65%. The business had revenue of $336.14 million during the quarter, compared to analysts’ expectations of $303.91 million. As a group, equities analysts forecast that Axon Enterprise, Inc. will post 1.59 earnings per share for the current fiscal year.
Axon Enterprise Company Profile
Axon Enterprise, Inc engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services.
- Get a free copy of the StockNews.com research report on Axon Enterprise (AXON)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON – Get Rating).
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.